Short answer

Singapore’s HSA and Malaysia’s MDA signed a regulatory reliance MoU on 22 August 2025 and piloted it until 28 February 2026. Since 1 March 2026, MDA accepts Class B, C and D devices registered on the Singapore Medical Device Register through its verification route, which MDA calls full implementation; neither regulator calls it permanent. EU MDR certified software rarely needs Singapore first: the EU certificate qualifies for HSA’s abridged route and for MDA’s verification route, so both submissions can run in parallel from the same evidence. Each country still needs its own local party: a registrant in Singapore and a licensed, GDPMD-certified Authorised Representative in Malaysia.

What changed on 1 March 2026 — and why it matters for your SaMD

HSA and Malaysia's Medical Device Authority (MDA) signed a Memorandum of Understanding on 22 August 2025, at the 14th ASEAN Medical Device Committee meeting, and ran a six-month pilot of their Medical Device Regulatory Reliance Programme from 1 September 2025 to 28 February 2026. MDA then announced that, with effect from 1 March 2026, applications for Class B, C and D devices registered on the Singapore Medical Device Register (SMDR) continue to be accepted through its verification route. MDA describes this as full implementation; HSA states that it is committed to the ongoing implementation of the programme.

The programme works in both directions:

  • Malaysia relying on Singapore: devices registered with HSA can use MDA's conformity assessment by way of verification (MDA/GD/0070). HSA describes the expected Conformity Assessment Body (CAB) review as 30 working days, against 60 working days for a full conformity assessment, followed by registration within 30 working days.
  • Singapore relying on Malaysia: devices registered with MDA can be submitted on HSA's abridged route, which HSA describes as up to 30% shorter than the full route. It covers Class B, C and D devices that have completed full conformity assessment by an MDA CAB and MDA evaluation; devices classified differently by the two regulators and Class D devices with a registrable drug are excluded. You opt in on SHARE under "Evaluation Route Determinants".
If you already hold EU MDR certification: both regulators already accept your EU certificate. HSA lists EU Notified Body certificates among its reference approvals for the abridged route, and MDA's list of recognised approvals for the verification route includes EU MDR certificates. For an EU MDR certified SaMD the HSA–MDA programme is therefore a convenience, not a precondition — you can run Singapore and Malaysia in parallel. The SMDR route matters mainly where your HSA registration is the relevant reference, for example if your EU certificate does not cover the same device or intended purpose.

Step by step for EU MDR certified SaMD

Step 1: EU MDR certification as your foundation

With an EU Notified Body certificate for the same labelled use, a Class B–D device normally qualifies for HSA's abridged route. Your MDR technical documentation, clinical evaluation and ISO 13485 certificate are the evidence base for the Singapore submission — and the same evidence supports the Malaysian verification route.

HSA's software guideline GL-04 Revision 4 (effective 31 December 2025) sets out its expectations for software lifecycle documentation, cybersecurity (it encourages IEC 81001-5-1 and adds explicit operating system end-of-support requirements), machine-learning-enabled devices and change management. If your technical file was built to MDR Annex II and III, most of the content exists; typical additions are the CSDT structure, Singapore declarations, the OS end-of-support points and Singapore-specific post-market procedures. Our Singapore HSA SaMD registration guide covers this in detail.

Step 2: Singapore HSA registration via SHARE

Submit the product registration application through HSA's SHARE online system. A Singapore registrant — a local company such as your subsidiary, a distributor or an independent registrant — applies for and holds the registration on your behalf; importing and wholesale supply additionally require HSA dealer licences.

Classification follows HSA's Class A–D framework (GN-13; GL-07 for clinical decision support software). HSA's target turnaround times on the abridged route are 100 (Class B), 160 (Class C) and 220 (Class D) working days, excluding the time you take to answer queries; on the full route they are 160, 220 and 310.

Once registered, your device is listed on the Singapore Medical Device Register (SMDR) — the listing that MDA's verification route recognises under the HSA–MDA programme.

Step 3: Malaysia MDA registration via the verification route

Your Malaysian Authorised Representative (AR) appoints an MDA-registered CAB to perform conformity assessment by way of verification, as described in MDA/GD/0070 (second edition, October 2025). The CAB verifies the manufacturer's evidence — QMS, post-market data, technical documentation and Declaration of Conformity — instead of performing a full conformity assessment, and issues a certificate of conformity valid for five years. The AR then submits the registration application in MeDC@St; MDA's guidance gives 30 working days for its decision on a complete Class B–D application.

Either your EU MDR certificate or your SMDR listing can serve as the recognised approval. Conditions include the same design and intended purpose as the approved device, no associated safety issues worldwide in the last year (no deaths, serious deterioration in health or open field safety corrective actions) and no rejection or withdrawal by a recognised authority. MDA charges an application fee and a registration fee for a five-year registration — for example RM 250 + RM 1,000 for Class B and RM 500 + RM 2,000 for Class C; CAB fees are set by each CAB.

Official targets at a glance: HSA abridged route — 100, 160 and 220 working days for Class B, C and D (excluding stop-clock). MDA verification route — approximately 1.5 months for the CAB step and 30 working days for MDA's decision on a complete Class B–D application. These are regulator targets, not guarantees; elapsed time depends on dossier quality and query rounds.

We support EU-certified software companies through both submissions in our Singapore HSA and Malaysia MDA registration service.

What HSA requires beyond EU MDR documentation

Your EU MDR technical file covers most of what HSA needs, but several additions are required for a Singapore submission:

  • HSA declarations and authorisation letter: GN-15 provides templates for the letter of authorisation and for the declarations HSA expects (marketing history, safety, and labelling/adverse events/field safety corrective actions). Your EU Declaration of Conformity does not replace them.
  • Labelling: check labels and IFU against HSA's requirements. For software, GL-04 Revision 4 also expects the operating system requirements on the labelling and, for machine-learning-enabled devices, transparency information for users.
  • Updated cybersecurity documentation: GL-04 Revision 4 strengthened the cybersecurity expectations, including operating system end-of-support. If your cybersecurity documentation predates December 2025, update it to address OS end-of-support explicitly.
  • ASEAN Common Submission Dossier Template (CSDT): HSA uses the CSDT (guidance GN-17). Your EU MDR Annex II documentation maps onto it, but the CSDT has its own section headings and ordering.
  • Post-market obligations and change notification: Singapore's change notification rules (GN-21, now Revision 7) and the optional Change Management Program for SaMD (GN-37, since December 2024; covers ML-enabled SaMD but not continuous learning) differ from EU practice. You need Singapore-specific procedures for change notification, adverse event reporting (GN-05) and field safety corrective actions (GN-10).

The Malaysia layer: what MDA adds beyond HSA requirements

Under the verification route the CAB verifies existing evidence rather than repeating a full conformity assessment. Several Malaysia-specific requirements still apply:

  • Malaysian Authorised Representative: a foreign manufacturer must authorise an AR that is licensed and domiciled in Malaysia and holds an MDA establishment licence; the AR submits in MeDC@St and cannot be the brand owner. See our Malaysia MDA registration guide for AR selection.
  • Malaysia-specific labelling: under MDA/GD/0026 (7th edition, May 2026) the Malaysian registration number must appear on labelling within six months of registration; English is required for devices other than home-use devices, and Bahasa Malaysia for home-use devices.
  • Declaration of Conformity in MDA format: prepared according to Appendix 3 of the Third Schedule to the Medical Device Regulations 2012 (see MDA/GD/0025), in addition to your EU and Singapore documents.
  • GDPMD of your AR: MDA sets Good Distribution Practice for Medical Devices (GDPMD) as the quality system requirement for ARs, importers and distributors, certified by a CAB. Verify your AR's establishment licence and GDPMD certificate before submitting.

Singapore as a gateway beyond Malaysia

The HSA–MDA programme is part of a wider shift towards regulatory reliance in ASEAN. As of October 2026, a Singapore registration supports these routes:

  • Malaysia: verification route for SMDR-listed Class B, C and D devices — full implementation from 1 March 2026 (as covered in this guide)
  • Philippines FDA: abridged processing for Class B, C and D devices approved by the regulator of any ASEAN Member State, including HSA (FDA Circular No. 2022-008)
  • Thailand FDA: via Malaysia — MDA and Thai FDA moved their reliance programme to full implementation on 1 May 2026, so an MDA registration can skip Thai FDA's external expert evaluation

None of these is automatic: each country still issues its own registration and needs its own local party. For the regional picture, see our ASEAN market entry guide for EU MDR certified SaMD.

Official sources & references